select trial semaglutide cardiovascular outcomes non-diabetic 2023 Beyond obesity: Novo's re-defines risk management Semaglutide and Cardiovascular Outcomes in

There is no evidence of lasting metabolic suppression beyond normal weight loss adaptation

The anticipated transition to FDA-approved semaglutide injections will involve a large population of patients

In the STEP UP trial, patients taking the 7.2 mg dose lost between 19% and 21% of their starting weight on average [1]

Regional Insights North America Ischemic Optic Neuropathy Treatment Market Trends North America ischemic optic neuropathy treatment market is expanding rapidly and is projected to account for 38.9% of the global market share by 2025

Side Effects: GLP-1 medications can sometimes cause side effects such as nausea, vomiting, diarrhea, or dizziness